Both IL-15 and IL-2 are good options for cancer therapy, but IL-15 is considered superior due to lower vascular endothelial toxicity, stronger ability to expand natural killer and CD8+ T cells and weaker stimulation of T regulatory cells, but it has a short half-life and exerts severe adverse effects.
KAT6A and its paralogue KAT6B are histone acetyltransferases whose overexpression is linked to poor prognosis in ER+/HER2- breast cancer and other types of tumors.
Beijing QL Biopharmaceutical Co. Ltd. has presented preclinical data on their GLP-1/GDF15 dual agonist QL-1005 for the potential treatment of inflammation and fibrosis in murine models of metabolic dysfunction-associated steatohepatitis (MASH) and chemically induced liver fibrosis.
Immunity is not a function most people particularly associate with the liver. But because of its connection to the gut, the liver is exposed to bacterial metabolites as few other organs are. And when either the liver or the gut is not functioning well, it can adversely affect immunity as well. The liver is connected to the gut via both the biliary system and the portal vein. Those two conduits allow metabolites from the gut microbiome to influence what’s going on in the liver. Both liver and gut damage can affect this communication for the worse. And surprisingly, one of the consequences is immune dysfunction.
Folate receptor α (FOLR1) is highly expressed in the surface of tumoral cells in several cancer types, while it shows limited expression in normal tissues. CSPC Pharmaceutical Group Ltd. has developed a next-generation antibody-drug conjugate (ADC) targeting FOLR1 – SYS-6041 – for the treatment of mid-to-low FOLR1-expressing tumors.
Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.
Claudin-6 (CLDN6) is a protein found in the tight junctions of epithelial cells to modulate their permeability and barrier function, among other actions.
The progression of neurodegeneration during experimental glaucoma is tied to the early degradation of anterograde transport along retinal ganglion cells to central brain targets, which is followed by frank optic nerve degeneration.
The KRAS G12D mutation is the most common oncogenic KRAS variant, identified in approximately 34% of pancreatic ductal adenocarcinoma cases, 12% of colorectal cancers and 4% of lung adenocarcinomas.
Ongoing policy issues in the U.S., including the Inflation Reduction Act and recent proposals under President Donald Trump’s administration, have wide ranging implications for the global biopharmaceutical industry, speakers at Bio Korea 2025 said May 8, including a heightened need for all biotechs to draft regulatory strategies.
RSS
